NCENational nstitute forHealth and Care ExcellenceNICE贝guidanceOlaparib for adjuvanttreatment of BRCAmutation-positiveHER2-negative high-riskearly breast cancer afterchemotherapyTechnology appraisal guidancePublished:10 May 2023www.nice.org.uk/quidance/ta886NICE 2023.All rights reserved.Subject to Notice of rights (https://www.nice.org.uk/temms-and-conditions#notice-of-rights).